Prometheus® European liver disease outcome study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN50777531

Enrollment

200

Registered

2005-09-20

Start date

2005-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe deterioration of chronic liver disease. Urological and Genital Diseases Liver disease

Interventions

Patients will be randomised to either standard medical treatment or to Prometheus® treatment in addition to standard medical treatment. For more information, please contact Dr Kinan Rifai at Medizini

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with severe deterioration of chronic liver disease.

Exclusion criteria

Exclusion criteria: Conditions strongly interfering with the study outcome (e.g. active HCC, extrahepatic malignancy).

Design outcomes

Primary

Measure	Time frame
Patient survival.	—

Secondary

Measure	Time frame
Clinical course of the patient (e.g. length of stay in intensive care/in hospital, number of hospital re-admissions, liver transplantation status, laboratory parameters).	—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026